The Pharma Data

DECEMBER 16, 2020

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

Protein 40

Protein Bioinformatics Containment Drugs 40

pharmaphorum

MARCH 28, 2022

Via its third call for applications, AION and BioMed X aims to entice innovative thinkers to find ways to develop solutions to common pharma challenges by analysing existing antibody therapies to make new efficient and effective therapies using AI. Then, a development stage or optimisation stage occurs.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

pharmaphorum

SEPTEMBER 14, 2020

Through his work at the Wellcome Sanger Institute and Congenica, and involvement with the 100,000 Genomes Project, Charlie has been well placed to see the development of genomics over the years and the promises that it will bring to healthcare. Luckily there have been some encouraging developments in sequencing technology in recent years.

Genomics 119

Genomics Genome Medicine Gene 119

Scienmag

OCTOBER 27, 2020

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5

Drugs 59

Drugs Protein Engineer Scientist 59

pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78

Trials Genome Genomics Bioinformatics 78

Scienmag

JULY 1, 2021

Almost twenty years ago, the process of RNA silencing was discovered in plants, whereby small fragments of RNA inactivate a portion of a gene during protein synthesis.

RNA 60

RNA Protein Research Gene 60

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genomics 52

Genomics Genome RNA Genome Project 52

STAT News

MARCH 6, 2023

Cambridge-based Moderna recently reported encouraging results from a study of another type of personalized cancer vaccine it developed with the pharmaceutical giant Merck; it uses messenger RNA technology to target advanced melanoma. Neoantigen vaccines are designed to target certain proteins called neoantigens on tumor cells.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

Scienmag

AUGUST 11, 2020

Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.

Bacteria 41

Bacteria Genomics Genome Protein 41

The Pharma Data

JULY 27, 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,

Production 52

Production Antibody Sales Development 52

XTalks

NOVEMBER 7, 2022

In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments. During the webinar, Dr. Bahassi gave a brief schematic of how personalized, targeted assays can be developed to detect somatic mutations from cfDNA ( Figure 1 ).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

JANUARY 10, 2021

His company is leveraging the novel cellular immunotherapy development platform he invented to develop novel, targeted, allogeneic cell therapies against cancer with NK cells, the body’s immune cells that specialize in recognizing and attacking cancer cells. Can we develop…almost a preventative therapeutic approach?

Vaccination 52

Vaccination Vaccine Regulation Drugs 52

The Pharma Data

SEPTEMBER 1, 2020

head of Immunology and Fibrosis Development, Bristol Myers Squibb. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Author: Minton. Author: Harris.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

XTalks

MARCH 11, 2025

Erica Dawson Chief Research and Development Officer InDevR In this Xtalks Spotlight interview, Dr. Erica Dawson, Chief Research and Development Officer at InDevR, shared her insights on the current landscape of mRNA analytics and the potential breakthroughs that could support the future of multivalent vaccine development.

Vaccination 64

Vaccination Vaccine Development Manufacturing 64

Roots Analysis

JANUARY 27, 2025

Protein therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. Considering their vast potential, close to 50% of the top selling drugs in 2023 were protein therapeutics.

Protein 40

Protein Reagent Marketing Gene 40